Theralase® therapeutic laser systems have received full clearance by all major regulatory agencies for adjunctive use in pain therapy. Its effectiveness as a low level laser therapy (LLLT) medical device has been demonstrated through successful patient treatments in healthcare clinics around the world, supported by evidence established through over 4,000 clinical studies. An example of this evidence was a clinical study ("Laser Therapy Applications for Chronic Joint Pain") submitted to the FDA by Theralase® Technologies to demonstrate the application of laser therapy for chronic joint pain. This randomized placebo controlled clinical trial was completed with the objective of evaluating the Theralase® LLLT medical device as an adjunctive modality to standard treatment for knee pain using chiropractic techniques. The data obtained in the study clearly demonstrated that the Theralase® therapeutic laser provided significant relief and improvement in all of the primary evaluation criteria from chronic pain associated with knee disorders.
The Theralase® low-cost series are smaller, lighter units able to activate all three known cellular pathways providing superb clinical outcomes at a lower cost than a traditional Theralase® laser system. The TLC-100 & 300 are battery powered while the TLC-900 uses a power cord.